Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase NA 1 Phase 4 1 Phase 3 1

Status

Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 299 Cisplatin 298 Paclitaxel 257 Radiotherapy 255 Fluorouracil 234 Carboplatin 234 Docetaxel 230 Doxorubicin 216 Dexamethasone 166 Gemcitabine 156 Vincristine 147 Etoposide 136 Leucovorin 133 Capecitabine 129 Bevacizumab 129 Prednisone 125 Rituximab 118 Methotrexate 118 Cytarabine 110 Filgrastim 99 Trastuzumab 97 Oxaliplatin 96 pembrolizumab 83 Pemetrexed 73 Epirubicin 70 Tamoxifen 69 Drug Therapy 69 Irinotecan 65 Granulocyte Colony-Stimulating Factor 60 Daunorubicin 58

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Completed × Fumigant 93 × Clear all

NCT02504489 2026-05-19

DUBLIN-3

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed

559 enrolled 32 charts

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡